Regeneron Historical Cash Flow
| REGN Stock | USD 750.22 4.65 0.62% |
Analysis of Regeneron Pharmaceuticals cash flow over time is an excellent tool to project Regeneron Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Capital Expenditures of 972.7 M or Total Cash From Operating Activities of 4.8 B as it is a great indicator of Regeneron Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Regeneron Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Regeneron Pharmaceuticals is a good buy for the upcoming year.
Regeneron |
About Regeneron Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Regeneron balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Regeneron's non-liquid assets can be easily converted into cash.
Regeneron Pharmaceuticals Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Regeneron Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Regeneron Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Regeneron Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Regeneron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.At this time, Regeneron Pharmaceuticals' Net Income is very stable compared to the past year. As of the 1st of December 2024, End Period Cash Flow is likely to grow to about 2.9 B, though Change In Cash is likely to grow to (362.5 M).
Regeneron Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Regeneron Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Regeneron Pharmaceuticals cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 150.1M | 577M | 690.8M | 221.3M | (381.6M) | (362.5M) | |
| Free Cash Flow | 2.0B | 2.0B | 6.5B | 4.4B | 3.7B | 3.9B | |
| Change In Working Capital | (200.5M) | (1.5B) | (1.9B) | (243.3M) | (94.1M) | (98.8M) | |
| Begin Period Cash Flow | 1.5B | 1.6B | 2.2B | 2.9B | 3.1B | 3.3B | |
| Other Cashflows From Financing Activities | (188M) | (70.6M) | (5.4B) | (3.8B) | (3.2B) | (3.0B) | |
| Depreciation | 210.3M | 235.9M | 286.2M | 341.4M | 421M | 442.1M | |
| Other Non Cash Items | (29.3M) | (135M) | 181.7M | 599.8M | 266.3M | 279.6M | |
| Capital Expenditures | 429.6M | 614.6M | 551.9M | 590.1M | 926.4M | 972.7M | |
| Total Cash From Operating Activities | 2.4B | 2.6B | 7.1B | 5.0B | 4.6B | 4.8B | |
| Net Income | 2.1B | 3.5B | 8.1B | 4.3B | 4.0B | 4.2B | |
| Total Cash From Financing Activities | (252.1M) | (2.0B) | (1.0B) | (1.0B) | (1.8B) | (1.7B) | |
| End Period Cash Flow | 1.6B | 2.2B | 2.9B | 3.1B | 2.7B | 2.9B | |
| Change To Inventory | (335.5M) | (529.4M) | (494.3M) | (696.5M) | (271.7M) | (258.1M) | |
| Change To Account Receivables | (473.1M) | (1.4B) | (1.9B) | 707.8M | (338.8M) | (355.7M) | |
| Sale Purchase Of Stock | (463.9M) | (6.5B) | (2.7B) | (2.5B) | (2.9B) | (2.8B) | |
| Total Cashflows From Investing Activities | (2.0B) | (70.6M) | (5.4B) | (3.8B) | (3.4B) | (3.2B) | |
| Stock Based Compensation | 464.3M | 432M | 601.7M | 725M | 885M | 929.3M | |
| Investments | (1.6B) | 544M | (4.8B) | (1.9B) | (5.0B) | (4.7B) | |
| Cash And Cash Equivalents Changes | 150.1M | 577M | 690.8M | 221.3M | 254.5M | 245.4M | |
| Change To Netincome | 314.2M | (895.1M) | (994M) | 676.5M | 608.9M | 639.3M | |
| Change To Operating Activities | (130.4M) | 114.9M | (240.7M) | (148.6M) | (133.7M) | (127.1M) | |
| Change To Liabilities | 738.5M | 267M | 745.9M | (106M) | (95.4M) | (90.6M) | |
| Issuance Of Capital Stock | 211.8M | 2.6B | 1.7B | 1.5B | 1.2B | 1.3B |
Pair Trading with Regeneron Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regeneron Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regeneron Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Regeneron Stock
Moving against Regeneron Stock
| 0.94 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.87 | GILD | Gilead Sciences | PairCorr |
| 0.85 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.78 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.72 | BHC | Bausch Health Companies | PairCorr |
The ability to find closely correlated positions to Regeneron Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regeneron Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regeneron Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regeneron Pharmaceuticals to buy it.
The correlation of Regeneron Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regeneron Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regeneron Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Regeneron Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.298 | Earnings Share 40.44 | Revenue Per Share 128.691 | Quarterly Revenue Growth 0.106 | Return On Assets 0.0741 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.